Search Results

You searched for : BoehringerIngelheim

	Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation The company also announced the planned initiation of the innovative CONNEX Phase III clinical trial program assessing the safety and efficacy of BI 425809 ... May 27
	New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
	Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets Empagliflozin and Linagliptin tablets, have an estimated market size of US$ 244 million for twelve months ending June 2020... Aug 27
	Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio Boehringer Ingelheim Acquires Northern Biologicsâ€™ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio ... May 16
	Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
	Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies ... Sep 21
6 Matching result(s) found!

-Advertisements-

Trending Now
	FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
	Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
	Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024
	10 Strategies to counter disinformation for the healthcare digital ecosystemApril 23, 2024
	Is Selling Over-the-Counter (OTC) Drugs in General Stores A Step Towards Affordable Healthcare in IndiaApril 23, 2024
	Student Health Crisis: Food Poisoning Incident Strikes Pune Coaching CentreApril 23, 2024
	The Impact of Diabetes on Kidney Health: Diabetic Nephropathy ExplainedApril 23, 2024
	Toddler Hospitalized After Consuming Expired Chocolates: Health Concerns RaisedApril 23, 2024
	After months of diagnostic delay, a migrant worker could access TB services only when a community health worker met himApril 22, 2024
	Indian Spices Contaminated with Cancer-Causing Chemical: Hong Kong Food Regulators Issue WarningApril 22, 2024
	FTCCI organised a Workshop on Rooftop Kitchen GardeningApril 20, 2024
	Children in Cities Exposed to Elevated Lead Levels: Study Reveals Urgent Health ConcernApril 20, 2024
	Biocon Ventures into Weight-Loss Drug Market with Semaglutide DevelopmentApril 20, 2024
	Innovative AI Assistance Empowers Moscow Doctors to Detect Cervical Spine Issues through MRI ScansApril 20, 2024
	Air India Express ties up with AISATS for AeroWash Automated Aircraft Exterior Cleanings April 19, 2024
	IndoSup raises strategic funding led by CCI group promoters Naresh Sharma and Satish Sharma; investors include Yatra.com’s Rohan Mittal April 19, 2024
	10 compelling reasons why choosing right media platform Is important in healthcareApril 19, 2024
	Protecting Public Health: Proposed Guidelines for Pharmaceutical Product DistributionApril 19, 2024
	What is Haemophilia: A Genetic Bleeding Disorder that has Affected 1,36,000 IndiansApril 19, 2024
	Climate Change and Stroke Risk: Exploring the Impact of Temperature Fluctuations on Your Body April 19, 2024

Search Results

Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets

Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Trending Now